Education
About Us
Working with TipRanks
Follow Us
Wave Life Sciences Pte. Ltd (WVE)
:WVE
WVE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.04 - $16.74
Previous CloseN/A
Volume104.35K
Average Volume (3M)1.92M
Market Cap
$1.30B
Enterprise Value$887.02M
Total Cash (Recent Filing)$208.48M
Total Debt (Recent Filing)$21.71M
Price to Earnings (P/E)―
Beta1.85
Next Earnings
Nov 06, 2025EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding159,140,460
10 Day Avg. Volume2,405,342
30 Day Avg. Volume1,916,043
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue9.44
Enterprise Value/Gross Profit9.44
Enterprise Value/Ebitda-6.58
Forecast
1Y Price Target
$18.23Price Target Upside122.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Bulls Say, Bears Say
Bulls Say
Clinical DataThe data showed good durability, with M-AAT increases and Z-AAT reductions sustained for at least four weeks in both single- and repeat-dose cohorts.
RNA Editing TechnologyWVE-006's good safety and editing efficiency provide encouraging validation for WVE's RNA editing technology to support three wholly owned GalNAc-conjugated AIMer programs to enter the clinic.
Safety ProfileWVE-006 was well tolerated with a favorable safety profile.
Bears Say
Editing EfficiencyThe sell-off on the AATD clinical update was due to lower editing efficiency from 200mg repeat dosing compared to what DNA editing has been able to achieve.
Stock PerformanceDespite the encouraging data, Wave's stock is down by nearly 20%, which is seen as an overreaction to unjustified threshold value ascribed for total AAT and M AAT levels.
Wave Life Sciences News
WVE FAQ
What was Wave Life Sciences Pte. Ltd’s price range in the past 12 months?
Wave Life Sciences Pte. Ltd lowest stock price was $5.04 and its highest was $16.73 in the past 12 months.
What is Wave Life Sciences Pte. Ltd’s market cap?
Wave Life Sciences Pte. Ltd’s market cap is $1.30B.
When is Wave Life Sciences Pte. Ltd’s upcoming earnings report date?
Wave Life Sciences Pte. Ltd’s upcoming earnings report date is Nov 06, 2025 which is in 61 days.
How were Wave Life Sciences Pte. Ltd’s earnings last quarter?
Wave Life Sciences Pte. Ltd released its earnings results on Jul 30, 2025. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.277 by -$0.033.
Is Wave Life Sciences Pte. Ltd overvalued?
According to Wall Street analysts Wave Life Sciences Pte. Ltd’s price is currently Undervalued.
Does Wave Life Sciences Pte. Ltd pay dividends?
Wave Life Sciences Pte. Ltd does not currently pay dividends.
What is Wave Life Sciences Pte. Ltd’s EPS estimate?
Wave Life Sciences Pte. Ltd’s EPS estimate is -0.26.
How many shares outstanding does Wave Life Sciences Pte. Ltd have?
Wave Life Sciences Pte. Ltd has 159,140,460 shares outstanding.
What happened to Wave Life Sciences Pte. Ltd’s price movement after its last earnings report?
Wave Life Sciences Pte. Ltd reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.277. Following the earnings report the stock price went down -1.923%.
Which hedge fund is a major shareholder of Wave Life Sciences Pte. Ltd?
Currently, no hedge funds are holding shares in WVE
Wave Life Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.23 (122.86% Upside)
$18.23 (122.86% Upside)
Blogger Sentiment
Bullish
WVE Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 69.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.6%
Last 30 Days ▲ 19.0%
Last 30 Days ▲ 19.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
59.76%
12-Months-Change
Fundamentals
Return on Equity
-171.41%
Trailing 12-Months
Asset Growth
20.85%
Trailing 12-Months
Company Description
Wave Life Sciences Pte. Ltd
Wave Life Sciences Ltd. is a biotechnology company focused on developing transformative medicines for patients with genetic diseases. The company specializes in precision medicine and leverages its proprietary technologies to design and develop oligonucleotide therapies targeting genetic disorders. Wave's core products include a pipeline of drug candidates aimed at treating various neurological and rare diseases, utilizing their innovative curvature technology to enhance therapeutic efficacy.
WVE Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected significant progress in clinical programs, particularly in INHBE for obesity and AATD. However, financial performance showed challenges with decreased revenue and increased net loss. The sentiment is balanced with both positive clinical updates and financial challenges.View all WVE earnings summariesWVE Stock 12 Month Forecast
Average Price Target
$18.23
▲(122.86% Upside)
Technical Analysis
Geron
―
Viridian Therapeutics
―
Syndax Pharmaceuticals
―
Dyne Therapeutics
―
Structure Therapeutics, Inc. Sponsored ADR
―
Ownership Overview
26.95% Insiders
13.14% Mutual Funds
0.08% Other Institutional Investors
53.06% Public Companies and Individual Investors